Abstract:β-Glucuronidase is a lysosomal enzyme and a molecular model of a class of therapeutics approved as enzyme replacement therapies for lysosomal storage diseases. Understanding the effect of bioreactor process variables on the production and quality of the biologics is critical for maintaining quality and efficacy of the biotherapeutics. Here, we have investigated the effect of three process variables, in a head-to-head comparison using a parallel bioreactor system (<em>n</em> = 8), namely 0.25 mM butyrate addition, a temperature shift (from 37 to 32 °C), and a pH shift (from 7.0 to 6.7) along with a control (pH 7, temperature 37 °C, and no additive) on the production and quality of human recombinant β-glucuronidase (GUS) by a Chinese hamster ovary (CHO) cell line. The study was performed as two independent runs (2 bioreactors per treatment per run; <em>n</em> ≤ 4). Although statistically not significant, protein production slightly increased with either 0.25 mM butyrate addition (13%) or pH shift (7%), whereas temperature shift decreased production (12%, not significant). Further characterization of the purified GUS samples showed that purification selectively enriched the mannose-6-phosphate (M6P)–containing GUS protein. Noticeably, a variation observed for the critical quality attribute (CQA) of the enzyme, namely M6P content, decreased after purification, across treatment replicates and, more so, across different treatments. The dimer content in the purified samples was comparable (~25%), and no significant discrepancy was observed in terms of GUS charge variants by capillary electrophoresis analysis. MALDI-TOF/TOF analysis of released N-glycans from GUS showed a minor variation in glycoforms among the treatment groups. Temperature shift resulted in a slightly increased sialylated glycan content (21.6%) when compared to control (15.5%). These results suggest that bioreactor processes have a differential effect, and better control is required for achieving improved production of GUS enzyme in CHO cells without affecting drastically its CQAs. However, the purification method allowed for enrichment of GUS with similar CQA profiles, regardless of the upstream treatments, indicating for the first time that the effect of slight alterations in upstream process parameters on the CQA profile can be offset with an effective and robust purification method downstream to maintain drug substance uniformity.

Process for Production of Recombinant Baboon Uricase in Escherichia Coli Rosetta (DE3)

Constructing Prokaryotic Vector of BC047440 Gene Expression and Purification of Its Recombinant Protein

Rationalization design, soluble expression and PEG modification of highly active recombinant human-porcine uricase mutant protein

Molecular Modification of Baboon Uricase to Reduce its Immunogenicity Employing Bovine Lactoferricin as Modifier

Efficient purification of a recombinant tag-free thermostable Kluyveromyces marxianus uricase by pH-induced self-cleavage of intein and expression in Escherichia coli

Cloning and Characterization of Purine Nucleoside Phosphorylase in Escherichia Coli and Subsequent Ribavirin Biosynthesis Using Immobilized Recombinant Cells

Recombinant Expression and Functional Assessment of Uricase from a Pertinent Origin of the Enzyme, Streptomyces sp. Strain 17-1

Microbial Uricase and its Unique Potential Applications

EFFICIENT PRODUCTION OF URIDINE 5′-DIPHOSPHO-N-ACETYLGLUCOSAMINE BY THE COMBINATION OF THREE RECOMBINANT ENZYMES AND YEAST CELLS

Functional expression and purification of bovine enterokinase light chain in recombinant Escherichia coli.

Improvement of uricase production from Bacillus subtilis RNZ-79 by solid state fermentation of shrimp shell wastes

High-yield expression, purification, characterization, and structure determination of tag-free Candida utilis uricase

Maximization of uricase production in a column bioreactor through RSM based optimization

Differential effects of bioreactor process variables and purification on the human recombinant lysosomal enzyme β-glucuronidase produced from Chinese hamster ovary cells

An Efficient System for Production of Recombinant Urokinase-Type Plasminogen Activator.

Rational design of a genome-based insulated system in Escherichia coli facilitates heterologous uricase expression for hyperuricemia treatment

Expression and purification of a novel therapeutic single-chain variable fragment antibody against BNP from inclusion bodies of Escherichia coli

[Expression and characterization of soluble recombinant Ulp1p with glutathione S-transferase tag in Escherichia coli]

Expression and purification of human urodilatin by small ubiquitin-related modifier fusion in Escherichia coli

Expression, purification and characterization of human urodilatin in E. coli.

Development of a rapid high-efficiency scalable process for acetylated Sus scrofa cationic trypsin production from Escherichia coli inclusion bodies